Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 5/20 | 0.68 |
| ▸ | CCR5 | P51681 | 4/20 | 0.68 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.36 |
| ▸ | ABL1 | P00519 | 3/20 | 0.35 |
| ▸ | BCR | P11274 | 3/20 | 0.35 |
| ▸ | MAPK7 | Q13164 | 4/20 | 0.34 |
| ▸ | FASN | P49327 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15849372 | 1.00 | CCR2 (0.68) | CCR2CCR5EPHX2ABL1BCR | |
| SCHEMBL15849346 | 1.00 | CCR2 (0.68) | CCR2CCR5EPHX2ABL1BCR | |
| SCHEMBL15849358 | 1.00 | CCR2 (0.68) | CCR2CCR5EPHX2ABL1BCR | |
| SCHEMBL26008297 | 1.00 | CCR2 (0.68) | CCR2CCR5EPHX2ABL1BCR | |
| SCHEMBL12627158 | 0.94 | CCR2 (0.61) | CCR2CCR5EPHX2ABL1BCR | |
| SCHEMBL3071900 | 0.92 | CCR2 (0.58) | CCR2CCR5 | |
| SCHEMBL15976603 | 0.92 | CCR2 (0.58) | CCR2CCR5 | |
| SCHEMBL10236005 | 0.92 | CCR2 (0.58) | CCR2CCR5 | |
| SCHEMBL15849351 | 0.92 | CCR2 (0.58) | CCR2CCR5 | |
| SCHEMBL15849373 | 0.92 | CCR2 (0.58) | CCR2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | CCR2 1/4885CCR5 5/4885EPHX2 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.